Bio-Rad Laboratories Inc. (BIO)

Schlusskurs vom Vortag:

$279.83

Offen:

$280.07

24-Stunden-Volumen:

136.93K

Marktkapitalisierung:

$8.06B

Einnahmen:

$2.67B

Nettoeinkommen (Verlust:

$-637.32M

KGV:

-48.12

EPS:

-5.85

Netto-Cashflow:

$218.26M

1W Leistung:

+1.55%

1M Leistung:

-13.30%

6M Leistung:

-2.58%

1J Leistung:

-26.95%

1-Tages-Spanne:

$280.00

$284.88

52-Wochen-Spanne:

$261.59

$431.79

Bio-Rad Laboratories Inc. Stock (BIO) Company Profile

Firmenname

Bio-Rad Laboratories Inc.

Sektor

Healthcare (1223)

Branche

Medical Devices (160)

Telefon

510-724-7000

Adresse

1000 Alfred Nobel Drive, Hercules

Mitarbeiter

8,000

Twitter

@BioRadLifeSci

Nächster Verdiensttermin

2024-05-14

Neueste SEC-Einreichungen

BIO's Discussions on Twitter

Bio-Rad Laboratories Inc. Stock (BIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-07	Eingeleitet	UBS	Buy
2023-06-16	Eingeleitet	Wells Fargo	Overweight
2022-12-07	Eingeleitet	RBC Capital Mkts	Outperform
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-01-28	Bestätigt	Citigroup	Buy
2020-01-08	Eingeleitet	Wells Fargo	Overweight
2020-01-07	Eingeleitet	Citigroup	Buy
2018-10-17	Eingeleitet	Goldman	Buy
2018-09-20	Eingeleitet	Morgan Stanley	Equal-Weight
2018-02-16	Herabstufung	CL King	Buy → Neutral
2017-07-13	Eingeleitet	Wells Fargo	Outperform
2017-06-28	Hochstufung	Deutsche Bank	Hold → Buy
2017-01-18	Eingeleitet	Deutsche Bank	Hold
2016-10-13	Eingeleitet	CL King	Buy
2015-05-06	Bestätigt	Jefferies	Buy
2009-12-18	Eingeleitet	Maxim Group	Buy
2009-11-06	Eingeleitet	Jefferies & Co	Buy
2009-07-17	Eingeleitet	Soleil	Buy
2007-09-26	Eingeleitet	Banc of America Sec	Buy
2007-02-23	Herabstufung	Robert W. Baird	Outperform → Neutral

Alle ansehen

Bio-Rad Laboratories Inc. Aktie (BIO) Neueste Nachrichten

Earnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline

Zacks Investment Research

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

New Strong Sell Stocks for April 19th

Zacks Investment Research

96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?

Benzinga

Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?

Zacks Investment Research

Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

Zacks Investment Research

Finanzdaten der Bio-Rad Laboratories Inc.-Aktie (BIO)

Bio-Rad Laboratories Inc. (BIO) Umsatz 2024

Bio-Rad Laboratories Inc. (BIO) Nettogewinn 2024

Bio-Rad Laboratories Inc. (BIO) Free Cashflow 2024

Bio-Rad Laboratories Inc. (BIO) Gewinn je Aktie 2024